Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia
- 31 December 1991
- journal article
- clinical trial
- Published by Elsevier in Bone and Mineral
- Vol. 15 (3), 257-266
- https://doi.org/10.1016/0169-6009(91)90131-i
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: A randomized comparison between a 3-day treatment and single 24-hour infusionsJournal of Bone and Mineral Research, 1989
- PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATEThe Lancet, 1989
- Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl)thiomethylene bisphosphonate, in the treatment of Paget's disease of boneBone, 1988
- Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chlorideAmerican Journal Of Medicine, 1987
- A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonateJournal of Bone and Mineral Research, 1986
- Serum osteocalcin (BGP) in tumor-associated hypercalcemiaJournal of Bone and Mineral Research, 1986
- Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.Journal of Clinical Oncology, 1986
- Tumor products and the hypercalcemia of malignancy.Journal of Clinical Investigation, 1985
- Monitoring the treatment of paget's disease with etidronateCalcified Tissue International, 1984
- EFFECTS OF INTRAVENOUS DIPHOSPHONATES ON RENAL FUNCTIONThe Lancet, 1983